![](https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg)
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
Roche announced that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO, branch RVO or central RVO). RVO is the third indication for Vabysmo in …